anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is two-arm parallel design randomized controlled trial. Participants will be selected by non-probability consecutive sampling technique, fifty stroke patients meeting the inclusion criteria will be randomly allocated into two groups (experimental and control) by online randomizer tool. The experimental group will receive tai chi exercises with cycling exercises and the control group will receive tai chi exercises alone. Treatment session of 60 min will be given 3 times a week for 6 weeks. The following primary and secondary assessment tools will be used, Functional Reach Test and Berg Balance scale for balance, Dynamic Gait Index and Wisconsin Gait Scale for gait assessment and Stroke Specific Quality of life (SS-QOL). The data will be analyzed using SPPS software version. 26.
Spinal and bulbar muscular atrophy (SBMA) progressively impairs gait function, resulting in the need for patients to use a wheelchair approximately 20 years after onset. No reports have investigated the effects of long-term exercise training using the Hybrid Assisted Limb (HAL) in patients with multiple SBMA. This study investigated the effects of long-term exercise training using HAL in patients with SBMA and its effects on the quality of life (QoL). Six courses of HAL treatment were administered to three males with SBMA, and leuprorelin was administered to each patient. Each course had a 4-5 week duration, during which the treatment was performed nine times, with a rest period of at least 2 months between each course. A 2-minute walk test (2MWT) and a 10-m walk test (10MWT) were performed to measure gait ability, and a blood test to measure the serum creatine kinase (CK) and creatinine (CRE) levels was performed before and after each course of treatment. We evaluated QoL using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). The average 2MWT distance improved over 2 years (p = 0.038), and the 10MWT showed neither improvement nor decline. No increase or decrease in serum CK or CRE levels was observed. There were no significant changes in the SF-36 physical, mental, or social summary scores. In combination with leuprorelin therapy, robot-assisted training using HAL maintained gait ability and QoL in patients with SBMA for 2 years.
ABSTRACT OF THE INVENTION      Mammalian GAP-43 cDNA has been cloned.   The nucleotide sequences  and corresponding amino acid  sequences for human GAP-43 as well as rat GAP-43 are disclosed.  The substantially pure sequences of the present invention may be expressed in prokaryotic and eukaryotic hosts, and are of use in monitoring and regulating neuronal growth in animals including humans.  A novel membrane-targeting peptide has been discovered, which is capable of directing any desired protein or peptide to the cell  membrane  of  neuronal  or  non-neuronal  cells.    The substantially pure sequences of the present invention are of use in therapeutic and diagnostic methods.            A104-01.WP                                          122189
Patients enrolled during the control blocks will receive antibiotics for respiratory infection at the provider's discretion in keeping with current standards of care. Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge.
OBJECTIVES: The purpose of this review is to investigate the relationship between gastrointestinal microbiome, obesity, and gestational diabetes mellitus (GDM) in an objective manner.
METHODS: We conducted a thorough and comprehensive search of the English language literatures published in PubMed, Web of Science, and the Cochrane Library from the establishment of the library until 12 December 2023. Our search strategy included both keywords and free words searches, and we strictly applied inclusion and exclusion criteria. Meta-analyses and systematic reviews were prepared.
RESULTS: Six high-quality literature sources were identified for meta-analysis. However, after detailed study and analysis, a certain degree of heterogeneity was found, and the credibility of the combined analysis results was limited. Therefore, descriptive analyses were conducted. The dysbiosis of intestinal microbiome, specifically the ratio of Firmicutes/Bacteroides, is a significant factor in the development of metabolic diseases such as obesity and gestational diabetes. Patients with intestinal dysbiosis and obesity are at a higher risk of developing GDM.
CONCLUSIONS: During pregnancy, gastrointestinal microbiome disorders and obesity may contribute to the development of GDM, with all three factors influencing each other. This finding could aid in the diagnosis and management of patients with GDM through further research on their gastrointestinal microbiome.
OBJECTIVES: Hepatitis delta virus (HDV) is a defective virus needing the envelope provided by hepatitis B virus (HBV) in order to enter liver cells and propagate. Chronic HDV infection is considered the most severe viral hepatitis, resulting in accelerated fibrosis progression until cirrhosis and its complications (hepatocellular carcinoma, liver decompensation) compared with HBV mono-infected patients. Off-label treatment with interferon has represented the only treatment option in the last 40 years, resulting in suboptimal virological response rates and being limited by safety issues especially in patients with advanced cirrhosis. Recently, the first HBV-HDV entry inhibitor Bulevirtide (BLV) has been approved by the European Medicines Agency (EMA) for treatment of chronic compensated HDV.
METHODS: This review summarises most recent updates on HDV epidemiology, diagnosis and treatment, with a special focus both on clinical trials and real-life studies about BLV. An overview on new HDV compounds under development is also provided.
RESULTS: BLV, the HBV-HDV entry inhibitor, has shown promising safety and efficacy data in clinical trials and in real-life studies, also in patients with advanced cirrhosis and portal hypertension. However, according to EMA label treatment is currently intended long-term until clinical benefit and predictors of responses are still undefined. The potential combination with PegIFNα seems to increase virological and clinical responses. New compounds are under development or in pipeline for treatment of HDV.
CONCLUSION: After more than 40 years since HDV discovery, new treatment options are currently available to provide efficient strategies for chronic hepatitis Delta.
Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The second matching approach selected all subjects in the registry with diabetes mellitus and available data to match participants who received AT-001 for gender, age group (in bings of 5 years), and weight (+/- 0.5 kgs).
A system and method for automatically adjusting medical displays is arranged to communicate medical information to a caregiver. The system includes at least one display for displaying medical information, a wireless communication device associated with the display and a wireless communication device associated with the caregiver. The wireless communication device associated with the display is arranged to realize if the wireless communication device associated with the caregiver, and thus the caregiver, is present in a predetermined area near the display. A controller associated with the display is arranged to automatically adjust at least one characteristic of the display based upon the realized presence of the caregiver. According to the method, the presence of the caregiver is detected when the caregiver enters the predetermined area near the display. At lease one characteristic of the display is thus adjusted automatically based upon the detected presence of the caregiver in the predetermined area.
Delirium is often missed because physicians do not routinely screen for this diagnosis. Most delirium assessments can take up to 10 minutes to perform making them less likely to be incorporated into the routine physician assessment. Using brief (\<2 minutes) and easy to use delirium assessments may ameliorate this quality of care issue. The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) possesses these characteristics, but has only been validated in mechanically and non-mechanically ventilated intensive care unit patients. As a result, it still requires validation in the non-ICU hospitalized patients. Recently, we also developed the Brief Confusion Assessment Method (B-CAM) which is a modification of the CAM-ICU. The benefit is that it takes even less time than the CAM-ICU. However, it also requires validation in hospitalized patients. As result, we propose the following and the following specific aims:

Aim #1: To validate the B-CAM in non-ICU hospitalized patients. The B-CAM will be performed by a clinical trials associate (CTA) and principal investigator in 150 non-ICU hospitalized patients that are \> 65 years old. This instrument will be validated against a psychiatrist's Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition Text Revision assessment as the reference standard.

Aim #2: To validate the CAM-ICU in non-ICU hospitalized patients. The CAM-ICU will be performed by a clinical trials associate (CTA) and principal investigator in approximately 150 non-ICU hospitalized patients that are \> 65 years old. This instrument will be validated against a psychiatrist's Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition Text Revision assessment as the reference standard.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to clinical cardiology and radiation diagnostics, and can be used for diagnosing acute myocardial infarction (AMI) by combined single-photon emission and X-ray computed tomography (SECT/CT). SECT is performed with radiopharmaceuticalTc-pyrophosphate (RF). CT is performed in low-dose or diagnostic mode. Projections are recorded 60-90 minutes after RF introduction. SECT mode includes number of projections – 32, 64×64 pixels matrix, recording time of one projection is 30 seconds. Projections are reconstructed to obtain tomographic images using the OSEM iterative algorithm. A simultaneous joint analysis of the SECT data and CT data is carried out, wherein the SECT data are used to construct the axial images, and the CT data are used as an anatomical reference point, which enables to separate the myocardium from the ventricular cavity. Using the SECT data, the acute myocardial injury area is defined as the RF accumulation area visually limited from the surrounding tissues, and the CT data are used to locate the acute myocardial infarction focus.EFFECT: invention provides higher sensitivity and diagnostic accuracy in detecting acute myocardial infarction.1 cl, 3 dwg
The present invention relates to novel uses of xanthine derivatives, more particularly pentoxiffyline, derivatives or metabolites thereof, alone or in combination with cytochrome P450 inhibitors, such as e.g. ciprofloxacin. They may be used for treating tumors, hormone-related disorders, neurological or auto immune diseases, for treating patients undergoing bone marrow transplantation or receiving toxic agents. They are useful in modulating the effects of internal and external stimuli on cells by reversing the effects of these stimuli on the short-term secondary messenger pathways. In particular, the compounds of Formula (I), lower elevated levels of unsaturated, non-arachidonate phosphatidic acid (PA) and diacylglycerol (DAG) derived from said PA within seconds of the primary stimulus and their contact with said cells. The modulatory effect depends on the nature of the target cell and the stimulus applied.
Post-acute care (PAC) encompasses the wide range of rehabilitative services used to restore a patient's maximal functional status following discharge from an acute hospitalization with the goal of restoring healthful aging. Approximately 40% of all hospitalized Medicare beneficiaries utilize PAC, accounting for 20% of all Medicare expenditures. PAC is a fast-growing segment of Medicare, and for some conditions, Medicare spending on PAC nearly equals that of the initial hospitalization, with skilled nursing facility (SNF) PAC accounting for most of these trends. The quality of SNF PAC is suspect, with substantial regional variation, insufficient physical therapy delivery, high readmission rates, poor attention to whole-person care, and poor patient experience. Given these concerns, some experts have called for national improvement.

The investigators propose a home-based PAC model that substitutes for treatment in a traditional SNF PAC facility. We believe that rehabilitation following hospitalization in one's home has several benefits: support tailored to one's actual living circumstances, an environment that encourages earlier mobilization, support of and interaction with family and caregivers, and psychosocial benefits of being at home. To promote aging in place, the investigators plan to deploy an innovative and tailored set of SNF PAC services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. The investigators plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license (certified nursing assistants, nurses, home health aides) with novel uses of technology (virtual physical therapy with three-dimensional camera feedback, continuous monitoring, and video visits).
Antibodies to biologically active peptides are claimed. The peptides, which are also cliamed, comprise partial sequences of the proliferation inhibitor mammary-derived growth inhibitor (MDGI). Peptide sequences are as follows: Peotide A (amino acids 69-78 of MDGI) EFDETTADDR. Peptide B (amino acids 121-131 of MDGI) TAVCTRVYEKQ. Peptide C (modified B) TRVCTRVYEKQ. Peptide D (modified B) TAVSTRVYEKQ. Also claimed is a method for the prodn.  of the antibodies by coupling the peptides to a carrier via a crosslinking agent, immunising a laboratory animal with the peptide construct, extracting antiserum, isolating the IgG fraction and isolating the specific antibodies by affinity chromatography. USE/ADVANTAGE - Useful in the study of the activity of MDGI (and related proteins), and have potential in the development of  similar proliferation regulators. The peptides have in vitro proliferation inhibiting activity against mammalian epithelial cells, a desensitising effect on coronary musculature and a beta-adrenergic effect. In an example, the inhibitory activity of peptide B is determined by measuring teh increase of carcinoma cells over 24 hrs. in the presence/absence of the peptide. At 10 power(-8) M inhibition is 17.1%, and at 10 power(-6) M inhibition is 33.3%. Addn. of insulin or cytidineoxyriboside reverses this activity.
The subject invention pertains to the development of a novel human mast cell line, USF-MC1. USF-MC1 is a mast cell precursor present in human umbilical cord blood (HUCB) that may be sustained in culture in the absence of exogenous cytokines to serve as a convenient experimental model of human mast cell activation. The SCF-independent human mast cell line USF-MC1 responds to IgE-mediated and IgE-independent stimuli in a way comparable to that of LAD2. USF-MC1 cells are useful for investigation of IgE-mediated activation mechanisms of human mast cells, contributing to the development of effective treatments for allergic disorders and other disorders. The subject invention provides a ready source of human mast cells for research, including pharmacological studies for the screening of various agents, and toxicologic, e.g., for the cosmetic and pharmaceutical industries. The mast cells can also be used as biofactories, for the large-scale production of biomolecules.
Washing with water and soap (standard care) will be replaced with two wash wipes during 30 days: (1) daily total body wash (using 3M Cavilon Bathing and Cleansing wipes) and (2) Continence Care (using 3M Cavilon Continence Care Wipes). No other preventive barrier or hydration products will be allowed in the genital-anal region.
The present invention provides compositions and methods of treating hepatitis virus infection, particularly hepatitis C virus infection. The invention provides methods of treating a hepatitis virus infection, involving administering a first form and a second form of IFN-α to provide a multiphasic pharmacokinetic profile. The multiphasic antiviral agent serum concentration profile that is achieved effects an initial rapid drop in viral titer, followed by a further decrease in viral titer over time, to achieve a sustained viral response. The invention further provides compositions that are effective in achieving a multiphasic IFN-α profile. Compositions of the invention comprise at least a first form of interferon-α (IFN-α) that has a first pharmacokinetic profile and a second form of IFN-α that has a second pharmacokinetic profile, where the second form of IFN-α has a longer mean residence time than that of the first form of IFN-α. The invention further provides compositions comprising C-terminally modified IFN-α.
TB Contouring The CT1, CT2, and US1 tumor beds will be manually contoured on the RM workstation by one of the study radiation therapists. Contouring will be performed using previously defined contouring guidelines. Available automatic contouring tools, including the 'interpolate' contouring function, may be utilized and contouring times will be recorded.

IGRT Assessment The patient will be set up on the breast board in treatment position. The 'ultra path' component of the Clarity system, which displays the path of the previous US acquired at CT simulation, will be used to guide the acquisition of US2. Although performed in the simulator room, the Clarity system will be used in 'treatment mode' thus simulating Clarity as it is used for IGRT. The study RT will first acquire the US2 scan. All steps following the acquisition of US2 will be performed off-line on the RM workstation without the need for further simulator or patient time.
Risk Summary

Discontinue niacin extended-release tablets when pregnancy is recognized in patients receiving the drug for the treatment of hyperlipidemia. Assess the individual risks and benefits of continuing niacin extended-release tablets during pregnancy in patients receiving the drug for the treatment of hypertriglyceridemia. Advise patients to inform their healthcare provider of a known or suspected pregnancy.

The potential for embryofetal toxicity with the doses of niacin in niacin extended-release tablets is unknown. The available data on niacin extended-release tablets use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with niacin or with niacin extended-release tablets. Treatment of hypercholesterolemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia for most patients. 

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
A device is disclosed for the application of oxygen to promote wound healing and tissue repair. The device includes a portable oxygen generating device for delivering oxygen to the wound site. The oxygen generating device generates high purity oxygen through electrochemical means and includes a cathode, an anode, and a phosphoric acid treated ion conducting membrane. The oxygen generating device may be driven by a power source which supplies current to the anode and cathode. Oxygen in the ambient air is reduced to water and/or peroxide in neutral or ionic forms. One or more of these species diffuse through the ion conducting membrane and is oxidized at the other electrode to produce high purity oxygen.
PURPOSE:To obtain a water-soluble bio-cream and bio-lotion by subjecting eggshell and a chitosan prepared from crab shell as natural organism resources, as raw materials, to a prescribed treatment. CONSTITUTION:Eggshell and a chitosan are treated with lactic acid to give a water-soluble bio-cream. A cream of eggshell raw material is diluted with approximately five times as much as purified water or ethanol and the prepared solution is mixed with a stock solution of a chitosan to give a bio-lotion. The eggshell used in this production is obtained by pulverizing eggshell containing shell membrane into a powdery state. The components of the eggshell powder are calcium carbonate constituting shell, a protein membrane stuck to the inside of the shell and fibrin penetrated in a root hair state into the shell. The chitosan is obtained by removing ash from crab shell and deproteinizing to give a chitosan and deacetylating the chitin. The cream and the lotion are bio-products consisting only of natural organism resources without requiring further addition of a humectant and a skin activating component.
Methods and Measures Patients 18 years of age and older presenting through the emergency room at Wake Forest University Baptist Medical Center with tibial and femoral fractures suitable for operative repair will be prospectively enrolled. Inclusion criteria will include any patient with a tibia fracture or femur fracture requiring intramedullary nailing. Retrograde intramedullary nails will be excluded as will nails which are not interlocked. The goal for enrollment is 24 tibial and 24 femoral fractures. Data including operative time, C-arm time, and "nail misses" will be obtained in the operating room for 24 tibial and 24 femoral nails. Surgeons who perform the procedure will have had experience using the freehand technique and will be trained with the guided wand prior to the experiment. Locking will be performed with the freehand and the wand technique in alternating order for the two interlocking screws. The order of which technique is utilized first will be randomly assigned. All procedures will be timed, and fluoroscopy time, radiation time, and any "nail misses" will be documented. All tibial nails will be locked with 2 mediolateral screws and all femurs with 2 lateral to medial screws.

Patients will receive follow-up for complications for a 6 month period after surgical procedure. Intervals of follow-up will be at 2 weeks, 6 weeks, 3 months and 6 months. Anterior-posterior and lateral images will be performed as are already customary and usual at these time intervals.

Outcome Measure(s) The goal is to prospectively assess the "wand" technique as a reliable alternative to standard interlocking screw placement which reduced operative time, C-arm exposure and inadvertent "nail misses." Additionally, it is expected that there will exist no complications related to the use of this technique.
NEW MATERIAL:6-Anilino-2,3-dihydro-5,8-dihydroxynaphthalene-1,4-dio-ne expressed by the formula. USE:A dye, pigment and an intermediate therefor capable of dyeing wool, hair, etc., to dark brown color, etc. PREPARATION:2-Anilino-5,8-dihydroxynaphthoquinone is reduced with a reducing agent, e.g. sodium dithionate, etc., in the presence of an alkali, e.g. KOH, NaOH or Na2CO3, etc., in water, alcohol or mixture solution of water and alcohol or in the presence of zinc in an aqueous solution of hydrochloric acid to afford the aimed compound expressed by the formula. The reaction condition is preferably at room temperature - refluxing temperature for 1-5hr under anaerobic condition to carry out the reaction.